Antimicrobial activity and chemical compositions of Turkish propolis from different regions

The antimicrobial activity of propolis against some gram-positive and gram-negative bacteria and its chemical composition were evaluated by the method of agar-well diffusion and GC-MS, respectively. Some typical compounds samples were identified in the propolis samples. Principal component analysis revealed that the chemical composition of propolis samples was distinct based on the geographical location of the samples. It was found that flavonoids, chrysin, flavanones and cinnamic acid were the predominant compounds in the propolis sample

Antioxidant and antimicrobial activities of Morchella conica Pers.

Antioxidant capacity and antimicrobial activities of Morchella conica Pers. extracts obtained with ethanol were investigated in this study. Four complementary test systems; namely DPPH free radical scavenging, -carotene/linoleic acid systems, total phenolic compounds and total flavonoid concentration were used. Inhibition values of M. conica ethanol extracts, buthylated hydroxyanisol (BHA) and -tocopherol standards were found to be 96.9, 98.9 and 99.2%, respectively, at aconcentration of 160 ìg/ml. When compared the inhibition levels of methanol extract of M. conica and standards in linoleic acid system, it was observed that the higher the concentration of both M. conicaethanol extract and the standards the higher the inhibition effect. Total flavonoid amount was 9.17±0.56ìg mg-1 quercetin equivalent while the phenolic compound amount was 41.93±0.29 ìg mg-1 pyrocatecholequivalent in the ethanolic extract. The antimicrobial effect of M. conica ethanol extract was tested against six species of Gram-positive bacteria, seven species of Gram-negative bacteria and one speciesof yeast. The M. conica ethanol extract had a narrow antibacterial spectrum against tested microorganisms. The most susceptible bacterium was M. flavus. The crude extract was found active on S. aureus ATCC 25923 and S. aureus Cowan I. The M. conica ethanol extract did not exhibit anticandidal activity against C. albican

VACCINATION PRACTICES OF ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS IN TURKEY.

[Abstract Not Available

Free-radical scavenging capacity and antimicrobial activity of wild edible mushroom from Turkey

Antioxidant capacity and antimicrobial activities of Ramaria flava (Schaeff) Quel. (RF) extracts obtained with ethanol were investigated in this study. Four complementary test systems; namely DPPH freeradical scavenging, -carotene/linoleic acid systems, total phenolic compounds and total flavonoid concentration have been used. Inhibition values of R. flava extracts, BHA and -tocopherol standardswere found to be 94.7, 98.9 and 99.2%, respectively, at 160ƒÊg/ml. When compared the inhibition levels of ethanol extract of R. flava and standards in linoleic acid system, it was observed that the higher theconcentration of both RF ethanol extract and the standards the higher the inhibition effect. Total flavonoid amount was 8.27}0.28 ƒÊg mg-1 quercetin equivalent while the total phenolic compound amountwas 39.83}0.32 ƒÊg mg-1 pyrocatechol equivalent in the ethanolic extract. The ethanol extract of R. flava inhibited the growth of Gram-positive bacteria better than Gram-negative bacteria and yeast. The crude extract showed no antibacterial activity against Pseudomonas aeruginosa, Escherichia coli, Morganella morganii and Proteus vulgaris. The antimicrobial activity profile of R. flava against tested strains indicated that Micrococcus flavus, Micrococcus luteus and Yersinia enterocolitica was the most susceptible bacteria of all the test strains. R. flava was found to be inactive against Candida albicans

PARADOXICAL REACTIONS, ESPECIALLY PSORIASIS IN RHEUMATOLOGY PATIENTS RECEIVING BIOLOGIC THERAPY FROM THE TREASURE DATABASE: A 5-YEAR FOLLOW-UP STUDY

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

BIOLOGIC DRUG PREFERENCES OF TURKISH RHEUMATOLOGISTS IN SPONDILOARTROPATHY PATIENTS WITH ADVANCED CHRONIC RENAL DISEASE

[Abstract Not Available

THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES - IMPLICATIONS FROM TREASURE DATABASE

EULAR European Congress of Rheumatology (EULAR) -- JUN 01-04, 2022 -- Copenhagen, DENMARK[Abstract Not Available]European Alliance Assoc Rheumato

Two-Center Review of Posterior Vault Expansion following a Staged or Expectant Treatment of Crouzon and Apert Craniosynostosis

Background: The timing of posterior cranial expansion for the management of intracranial pressure can be "staged" by age and dysmorphology or "expectant" by pressure monitoring. The authors report shared outcome measures from one center performing posterior vault remodeling (PCVR) or distraction (PVDO) following a staged approach and another performing spring-assisted expansion (SAPVE) following an expectant protocol. Methods: Apert or Crouzon syndrome patients who underwent posterior expansion younger than 2 years were included. Perioperative outcomes and subsequent cranial operations were recorded up to last follow-up and intracranial volume changes measured and adjusted using growth curves. Results: Thirty-eight patients were included. Following the expectant protocol, Apert patients underwent SAPVE at a younger age (8 months) than Crouzon patients (16 months). The initial surgery time was shorter but total operative time, including device removal, was longer for PVDO (3 hours 52 minutes) and SAPVE (4 hours 34 minutes) than for PCVR (3 hours 24 minutes). Growth-adjusted volume increase was significant and comparable. Fourteen percent of PCVR, 33% of PVDO, and 11% of SAPVE cases had complications, but without long-term deficits. Following the staged approach, 5% underwent only PVDO, 85% had a staged posterior followed by anterior surgery, and 10% required a third expansion. Following the expectant approach, 42% of patients had only posterior expansion at last follow-up, 32% had a secondary cranial surgery, and 26% had a third cranial expansion. Conclusion: Two approaches involving posterior vault expansion in young syndromic patients using three techniques resulted in comparable early volume expansion and complication profiles. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.</p